Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 8/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.59 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.59 |
| ▸ | THPO | P40225 | 1/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16306943 | 1.00 | PTGS1 (0.59) | PTGS1PTGS2MAPTCXCR1CXCR2 | |
| SCHEMBL31357336 | 1.00 | PTGS1 (0.59) | PTGS1PTGS2MAPTCXCR1CXCR2 | |
| SCHEMBL20669549 | 1.00 | PTGS1 (0.59) | PTGS1PTGS2MAPTCXCR1CXCR2 | |
| SCHEMBL3519007 | 0.89 | ALDH1A1 (0.47) | PTGS1PTGS2MAPTCXCR1CXCR2 | |
| SCHEMBL27634032 | 0.86 | ALDH1A1 (0.49) | PTGS1PTGS2MAPTCXCR1CXCR2 | |
| SCHEMBL602096 | 0.86 | PTGS2 (0.69) | PTGS1PTGS2MAPTCXCR1CXCR2 | |
| SCHEMBL11803372 | 0.85 | ALDH1A1 (0.47) | PTGS1PTGS2MAPTCXCR1CXCR2 | |
| SCHEMBL25268347 | 0.83 | ALDH1A1 (0.50) | PTGS1PTGS2MAPTCXCR1CXCR2 | |
| SCHEMBL9772448 | 0.83 | ALDH1A1 (0.46) | PTGS1PTGS2MAPTCXCR1CXCR2 | |
| SCHEMBL3926394 | 0.83 | PARP1 (0.48) | PTGS1PTGS2MAPTCXCR1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106083573-A | Organic ligand and preparation method, quantum dot, quantum dot layer and Light-Emitting Diode | 京东方科技集团股份有限公司 | 2016-11-09 | — | — | CN | claimed |
| US-12331023-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2025-06-17 | — | — | US | disclosed |
| WO-2025085564-A1 | LYSINE ACETYLTRANSFERASE INHIBITORS | Kronos Bio, Inc. (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025085560-A1 | LYSINE ACETYLTRANSFERASE INHIBITORS | Kronos Bio, Inc. (US) | 2025-04-24 | — | — | WO | disclosed |
| CN-112739695-B | Novel thiazole derivative and pharmaceutically acceptable salt thereof | 永进药品工业株式会社 | 2025-03-18 | — | — | CN | disclosed |
| US-12110299-B2 | Thiazole derivatives and pharmaceutically acceptable salts thereof | YUNGJIN PHARM. CO., LTD. (KR) | 2024-10-08 | — | — | US | disclosed |
| EP-4342540-A2 | SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS | Aurigene Oncology Limited (IN) | 2024-03-27 | — | — | EP | disclosed |
| CN-115141197-B | 3-aromatic heterocycle substituted phenyl derivative and preparation method and application thereof | 安徽医科大学 | 2024-03-26 | — | — | CN | disclosed |
| EP-3853225-B1 | N-(5-(3-(1-((THIAZOL-2-YL)AMINO)-1-OXOPROPAN-2-YL)PHENYL)PYRIDIN-2-YL)ACRYLAMIDE DERIVATIVES AS CDK7 INHIBITORS FOR THE TREATMENT OF CANCER | YUNGJIN PHARMACEUTICAL CO LTD (KR) | 2023-11-29 | — | — | EP | disclosed |
| EP-3853225-B1 | N-(5-(3-(1-((THIAZOL-2-YL)AMINO)-1-OXOPROPAN-2-YL)PHENYL)PYRIDIN-2-YL)ACRYLAMIDE DERIVATIVES AS CDK7 INHIBITORS FOR THE TREATMENT OF CANCER | YUNGJIN PHARMACEUTICAL CO LTD (KR) | 2023-11-29 | — | — | EP | disclosed |
| EP-1624868-A1 | \"(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)- PROPYL!PHENYL DERIVATIVES AS BETA2 AGONISTS | Pfizer Limited (GB) | 2006-02-15 | — | — | EP | disclosed |
| US-20050288344-A1 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. | 2005-12-29 | — | — | US | disclosed |
| US-20050234097-A1 | Compounds useful for the treatment of diseases | PFIZER INC | 2005-10-20 | — | — | US | disclosed |
| US-20050215542-A1 | Compounds for the treatment of diseases | PFIZER INC | 2005-09-29 | — | — | US | disclosed |
| EP-1545513-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004100950-A1 | ‘(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)-PROPYL!PHENYL DERIVATIVES AS BETA2 AGONISTS | PFIZER LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
| US-20040229904-A1 | Compounds useful for the treatment of diseases | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| WO-2004014316-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2004-02-19 | — | — | WO | disclosed |
| EP-0255178-A2 | Process for preparing hetero aryl and aryl alkanoic acids | Nobel Chemicals AB (SE) | 1988-02-03 | — | — | EP | disclosed |
| US-3985779-A | ANTIINFLAMMATORY AND ANALGESIC ACTIVITIES | EISAI CO., LTD. (JA) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234097-A1 | Compounds useful for the treatment of diseases | LTC4S, CYP11B2, CYP11B1 | PTGS1 26/4885PTGS2 78/4885MAPT 2364/4885 |
| US-20050288344-A1 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | TTPA, HAVCR2, ZC3HAV1 | PTGS1 542/4885PTGS2 895/4885MAPT 2383/4885 |
| US-12331023-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | CDK19, CDK9, CDK1 | PTGS1 2808/4885PTGS2 2705/4885MAPT 3255/4885 |
| US-12110299-B2 | Thiazole derivatives and pharmaceutically acceptable salts thereof | CDKL1, CDK4, CDKL3 | PTGS1 1597/4885PTGS2 2023/4885MAPT 2583/4885 |
| US-20040229904-A1 | Compounds useful for the treatment of diseases | LTC4S, CYP11B1, CYP11B2 | PTGS1 10/4885PTGS2 101/4885MAPT 3079/4885 |
| US-20050215542-A1 | Compounds for the treatment of diseases | LTC4S, LTB4R2, EPX | PTGS1 15/4885PTGS2 55/4885MAPT 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.